These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27849340)

  • 21. Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck.
    Rubinstein PG; Lindgren V; Setty S; Yao M; Pytynia KB; Radosevich JA; Kadkol SS; Feldman LE
    J Clin Oncol; 2011 Mar; 29(9):e222-5. PubMed ID: 21189379
    [No Abstract]   [Full Text] [Related]  

  • 22. Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer.
    Mennini FS; Marcellusi A; Fabiano G; Platini F; Bossi P
    Head Neck; 2019 Apr; 41(4):908-914. PubMed ID: 30680828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck.
    Chun SG; Hughes R; Sumer BD; Myers LL; Truelson JM; Khan SA; Ma TW; Xie Y; Yordy JS; Cooley S; Wu J; Choy H; Nedzi LA
    Cancer Invest; 2017 Jan; 35(1):23-31. PubMed ID: 27892728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma.
    Quan K; Xu KM; Zhang Y; Clump DA; Flickinger JC; Lalonde R; Burton SA; Heron DE
    Semin Radiat Oncol; 2016 Apr; 26(2):112-9. PubMed ID: 27000507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
    Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
    Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
    Kim S; Eleff M; Nicolaou N
    Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
    Seim NB; Kang SY; Bhandari M; Jones RG; Teknos TN
    Ann Otol Rhinol Laryngol; 2017 Apr; 126(4):334-339. PubMed ID: 28061634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
    Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
    Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of drug treatments for head and neck cancer.
    Galot R; Machiels JP
    Expert Opin Drug Saf; 2016 Nov; 15(11):1527-1539. PubMed ID: 27561463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center.
    Burke E; Rockey M; Grauer D; Henry D; Neupane P
    Med Oncol; 2017 Apr; 34(4):51. PubMed ID: 28229341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab and the Head and Neck Squamous Cell Cancer.
    Concu R; Cordeiro MNDS
    Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
    Swiecicki PL; Zhao L; Belile E; Sacco AG; Chepeha DB; Dobrosotskaya I; Spector M; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey T; Worden FP
    Invest New Drugs; 2015 Dec; 33(6):1248-56. PubMed ID: 26453566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective high-dose intra-arterial cisplatin as palliative treatment for incurable head and neck cancer.
    Teymoortash A; Bien S; Dalchow C; Sesterhenn A; Lippert BM; Werner JA
    Onkologie; 2004 Dec; 27(6):547-51. PubMed ID: 15591713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma.
    Omura G; Honma Y; Matsumoto Y; Shinozaki T; Itoyama M; Eguchi K; Sakai T; Yokoyama K; Watanabe T; Ohara A; Kato K; Yoshimoto S
    Auris Nasus Larynx; 2023 Aug; 50(4):641-645. PubMed ID: 35779979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer.
    Pfister DG; Bajorin D; Motzer RJ; Scher H; Louison C; Harrison L; Shah J; Strong E; Bosl G
    Invest New Drugs; 1993 Feb; 11(1):53-6. PubMed ID: 8349436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.